Overall rank by patents
#40,137
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Eyegate Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, active 2015–2019. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).
6
Total patents granted
5
CPC technology areas
12.0
Avg claims per patent
-100%
5-year filing velocity
The verdict
Eyegate holds 6 US patents across 5 technology areas, rank #40,137 of 50,000 tracked assignees.
- #40,137
- of 50,000 US assignees by volume
- Top 91%
- by Innovation Score (21.8/100)
- 12.0
- avg claims per patent
- -100%
- filing velocity, last 5 yrs
Portfolio overview
Eyegate Pharmaceuticals, Inc. has been granted 6 US utility patents between 2015 and 2019, placing Eyegate Pharmaceuticals, Inc. at rank #40,137 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.0 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a US Corporation, Eyegate Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Eyegate sits between Exosite Llc (6 patents, rank #40,133) and F.f. Seeley Nominees PTY Ltd. (6 patents, rank #40,141) - the closest US assignees by grant volume. The composite Innovation Score of 21.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 6 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Eyegate Pharmaceuticals, Inc.'s 12.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Eyegate Pharmaceuticals, Inc. against peers pursuing similar technology classes.
Who files at Eyegate's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Exosite
Exosite LLC
6 patents
- Expanding Innovat…
Expanding Innovations, Inc.
6 patents
- Expedera
Expedera, Inc.
6 patents
- Exuma Biotech
Exuma Biotech Corp.
6 patents
- Eyeprint Prosthet…
EyePrint Prosthetics LLC
6 patents
- F & M TOOL & Plas…
F & M TOOL & PLASTICS, INC.
6 patents
- F S Fehrer Automo…
F. S. FEHRER AUTOMOTIVE GMBH
6 patents
- F F Seeley Nomine…
F.F. SEELEY NOMINEES PTY LTD.
6 patents
- Eyegate Pharmaceu… ◀
EyeGate Pharmaceuticals, Inc.
6 patents
What this shows Eyegate holds 6 patents at rank #40,137, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Eyegate
By rank, the assignees closest to #40,137 in granted patent volume.
- Exosite Llc #40,133 · 6 patents
- Expanding Innovations, Inc. #40,134 · 6 patents
- Expedera, Inc. #40,135 · 6 patents
- Exuma Biotech Corp. #40,136 · 6 patents
- Eyeprint Prosthetics Llc #40,138 · 6 patents
- F & M TOOL & Plastics, Inc. #40,139 · 6 patents
- F. S. Fehrer Automotive Gmbh #40,140 · 6 patents
- F.f. Seeley Nominees PTY Ltd. #40,141 · 6 patents
Leaders in A61N (Electrotherapy)
Other assignees with the most granted patents in Eyegate's primary technology class.
- Medtronic, Inc. 2,200 in class
- Boston Scientific Neuromodulation Corporation 1,080 in class
- Cardiac Pacemakers, Inc. 1,037 in class
- Pacesetter, Inc. 609 in class
- ZOLL Medical Corporation 556 in class
- Koniniklijke Philips N.v. 534 in class
- Cochlear Limited 449 in class
- Varian Medical Systems, Inc. 296 in class
Eyegate's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
22 Top 91% higher than 9% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 33.3% |
| 2017 | 2 | 33.3% |
| 2018 | 1 | 16.7% |
| 2019 | 1 | 16.7% |
Which technologies does Eyegate Pharmaceuticals, Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Eyegate Pharmaceuticals, Inc. hold?
Eyegate Pharmaceuticals, Inc. holds 6 US granted patents filed between 2015 and 2019, spanning 5 technology areas.
What is Eyegate Pharmaceuticals, Inc.'s Innovation Score?
Eyegate Pharmaceuticals, Inc. has an Innovation Score of 21.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Eyegate Pharmaceuticals, Inc. focus on?
Eyegate Pharmaceuticals, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 6 patents. The company has filed patents in 5 CPC subclasses total.
Is Eyegate Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Eyegate Pharmaceuticals, Inc.'s recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Eyegate Pharmaceuticals, Inc.'s patents?
Eyegate Pharmaceuticals, Inc.'s patents average 12.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the Eyegate Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Eyegate's 6 grants land it in the top 91% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Eyegate ranks #40,137 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61N - see who else leads that technology area. A61N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.